CoChat
Sign Up
Cited by 61

The DOI matches its Crossref record.

Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment

Wang, Ruoning, Liang, Qifan, Zhang, Xinru, Di, Zhenning, Wang, Xiaohong, Di, Liuqing·2022·Colloids and Surfaces B: Biointerfaces
DOI 10.1016/j.colsurfb.2022.112505
Open this paper in CoChat — free account

Abstract

Temozolomide (TMZ), as the first-line chemotherapeutic agent, relies on inducing DNA methylation of O 6 -guanine for treating glioma. However, the survival time of patients are hardly exceeded 14.5 months, attributing to inevitable drug resistance and systematic toxicity after long-term administration. Herein, reassembly-exosomes (R-EXO) deriving from homologous glioma cells is proposed to carry TMZ and Dihydrotanshinone (DHT) for reversing drug resistance and enhancing lesions-targeted drug delivery, defined as R-EXO-TMZ/DHT (R-EXO-T/D). It is found that R-EXO-T/D share various advantages, including preferable blood-brain barrier (BBB)-penetrating ability with nanomemter size, tumor-homing accumulation with homologous effects, as well as potentiated antitumor activity with overcoming TMZ resistance and triggering immune response. This work develops a new strategy for site-specific drug delivery, showing a promising application of drug compatibility in glioma treatment.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.colsurfb.2022.112505

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 48

  1. Korgaonkar, 2019, Understanding the biology and advent of physics of cancer with perspicacity in current treatment therapy, Life Sci., 239, 10.1016/j.lfs.2019.117060 · DOI
  2. Fang, 2020, Arsenic trioxide as a novel anti-glioma drug: a review, Cell Mol. Biol. Lett., 25, 44, 10.1186/s11658-020-00236-7 · DOI
  3. Lu, 2018, A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system, Int J. Nanomed., 13, 5937, 10.2147/IJN.S175418 · DOI
  4. Shi, 2020, iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas, Biochem Biophys. Res Commun., 527, 117, 10.1016/j.bbrc.2020.04.064 · DOI
  5. da Hora, 2019, Patient-derived glioma models: from patients to dish to animals, cells, 8, 10.3390/cells8101177 · DOI
  6. Lara-Velazquez, 2017, Advances in brain tumor surgery for glioblastoma in adults, Brain Sci., 7, 10.3390/brainsci7120166 · DOI
  7. Wang, 2020, ‘Prodrug-Like’ Acetylmannosamine modified liposomes loaded with arsenic trioxide for the treatment of orthotopic glioma in mice, J. Pharm. Sci., 109, 2861, 10.1016/j.xphs.2020.06.001 · DOI
  8. Eslahi, 2021, The effects of chitosan-based materials on glioma: Recent advances in its applications for diagnosis and treatment, Int J. Biol. Macromol., 168, 124, 10.1016/j.ijbiomac.2020.11.180 · DOI
  9. Bi, 2018, β-catenin contributes to cordycepin-induced MGMT inhibition and reduction of temozolomide resistance in glioma cells by increasing intracellular reactive oxygen species, Cancer Lett., 435, 66, 10.1016/j.canlet.2018.07.040 · DOI
  10. Kohsaka, 2012, STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression, Mol. Cancer Ther., 11, 1289, 10.1158/1535-7163.MCT-11-0801 · DOI
  11. Kitange, 2009, Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts, Neuro Oncol., 11, 281, 10.1215/15228517-2008-090 · DOI
  12. Munoz, 2015, Temozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells, Cancer Lett., 367, 69, 10.1016/j.canlet.2015.07.013 · DOI
  13. Oldrini, 2020, MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas, Nat. Commun., 11, 3883, 10.1038/s41467-020-17717-0 · DOI
  14. Heravi Shargh, 2021, Chemosensitization of temozolomide-resistant pediatric diffuse midline glioma using potent nanoencapsulated forms of a N(3)-propargyl analogue, ACS Appl. Mater. Interfaces, 13, 35266, 10.1021/acsami.1c04164 · DOI
  15. Wang, 2021, Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia, J. Control Release, 338, 190, 10.1016/j.jconrel.2021.08.035 · DOI
  16. Chen, 2019, Pharmacological activities of dihydrotanshinone I, a natural product from Salvia miltiorrhiza Bunge, Pharm. Res, 145, 10.1016/j.phrs.2019.104254 · DOI
  17. Cao, 2017, Salvia miltiorrhiza extract dihydrotanshinone induces apoptosis and inhibits proliferation of glioma cells, Bosn. J. Basic Med Sci., 17, 235, 10.17305/bjbms.2017.1800 · DOI
  18. Kumar, 2017, Probing the oncolytic and chemosensitizing effects of dihydrotanshinone in an in vitro glioblastoma model, Anticancer Res, 37, 6025
  19. Bae, 2020, Advanced drug delivery 2020 and beyond: perspectives on the future, Adv. Drug Deliv. Rev., 158, 4, 10.1016/j.addr.2020.06.018 · DOI
  20. Moradi Kashkooli, 2020, Controlled anti-cancer drug release through advanced nano-drug delivery systems: static and dynamic targeting strategies, J. Control Release, 327, 316, 10.1016/j.jconrel.2020.08.012 · DOI · Paper page
  21. Wang, 2021, Nanoscale drug delivery systems for controllable drug behaviors by multi-stage barrier penetration, J. Control Release, 331, 282, 10.1016/j.jconrel.2020.08.045 · DOI
  22. Kopeček, 2020, Polymer nanomedicines, Adv. Drug Deliv. Rev., 156, 40, 10.1016/j.addr.2020.07.020 · DOI
  23. Yasaswi, 2021, Temozolomide nano enabled medicine: promises made by the nanocarriers in glioblastoma therapy, J. Control Release, 336, 549, 10.1016/j.jconrel.2021.07.003 · DOI
  24. Haney, 2015, Exosomes as drug delivery vehicles for Parkinson’s disease therapy, J. Control Release, 207, 18, 10.1016/j.jconrel.2015.03.033 · DOI · Paper page
  25. Herrmann, 2021, Extracellular vesicles as a next-generation drug delivery platform, Nat. Nanotechnol., 16, 748, 10.1038/s41565-021-00931-2 · DOI · Paper page
  26. Jang, 2021, Exosome-based photoacoustic imaging guided photodynamic and immunotherapy for the treatment of pancreatic cancer, J. Control Release, 330, 293, 10.1016/j.jconrel.2020.12.039 · DOI
  27. Huang, 2022, Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer, Mol. Cancer, 21, 45, 10.1186/s12943-022-01515-x · DOI
  28. Yong, 2019, Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy, Nat. Commun., 10, 3838, 10.1038/s41467-019-11718-4 · DOI · Paper page
  29. Gong, 2021, Tumor exosomes reprogrammed by Low pH Are efficient targeting vehicles for smart drug delivery and personalized therapy against their homologous tumor, Adv. Sci. (Weinh. ), 8
  30. Qiao, 2020, Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs, Theranostics, 10, 3474, 10.7150/thno.39434 · DOI · Paper page
  31. Wang, 2018, Exosomes released by hepatocarcinoma cells endow adipocytes with tumor-promoting properties, J. Hematol. Oncol., 11, 82, 10.1186/s13045-018-0625-1 · DOI
  32. Lu, 2020, Bioinspired exosome-like therapeutics and delivery nanoplatforms, Biomaterials, 242, 10.1016/j.biomaterials.2020.119925 · DOI
  33. Wang, 2019, Laser-triggered polymeric lipoproteins for precision tumor penetrating theranostics, Biomaterials, 221, 10.1016/j.biomaterials.2019.119413 · DOI
  34. Wang, 2018, Deep tumor penetrating bioparticulates inspired burst intracellular drug release for precision chemo-phototherapy, Small, 14
  35. Liu, 2019, Focused ultrasound-augmented targeting delivery of nanosonosensitizers from homogenous exosomes for enhanced sonodynamic cancer therapy, Theranostics, 9, 5261, 10.7150/thno.33183 · DOI
  36. Wang, 2020, An exosome-like programmable-bioactivating paclitaxel prodrug nanoplatform for enhanced breast cancer metastasis inhibition, Biomaterials, 257, 10.1016/j.biomaterials.2020.120224 · DOI
  37. Sun, 2018, Tumor exosomes: a double-edged sword in cancer therapy, Acta Pharm. Sin., 39, 534, 10.1038/aps.2018.17 · DOI
  38. Ren, 2016, From structures to functions: insights into exosomes as promising drug delivery vehicles, Biomater. Sci., 4, 910, 10.1039/C5BM00583C · DOI
  39. Zhang, 2019, The function of tumor-derived exosomes, J. buon, 24, 897
  40. Qiao, 2020, Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs, Theranostics, 10, 3474, 10.7150/thno.39434 · DOI · Paper page
  41. Fan, 2021, Carrier-free highly drug-loaded biomimetic nanosuspensions encapsulated by cancer cell membrane based on homology and active targeting for the treatment of glioma, Bioact. Mater., 6, 4402
  42. Kim, 2016, Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells, Nanomedicine, 12, 655, 10.1016/j.nano.2015.10.012 · DOI · Paper page
  43. Yin, 2015, Co-delivery of hydrophobic paclitaxel and hydrophilic AURKA specific siRNA by redox-sensitive micelles for effective treatment of breast cancer, Biomaterials, 61, 10, 10.1016/j.biomaterials.2015.05.022 · DOI
  44. Yong, 2019, Tumor exosome-based nanoparticles are efficient drug carriers for chemotherapy, Nat. Commun., 10, 3838, 10.1038/s41467-019-11718-4 · DOI · Paper page
  45. Gong, 2021, Tumor exosomes reprogrammed by low ph are efficient targeting vehicles for smart drug delivery and personalized therapy against their homologous tumor, Adv. Sci. (Weinh. ), 8
  46. Svensson, 2013, Exosome uptake depends on ERK1/2-heat shock protein 27 signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1, J. Biol. Chem., 288, 17713, 10.1074/jbc.M112.445403 · DOI
  47. Mulcahy, 2014, Routes and mechanisms of extracellular vesicle uptake, J. Extra Vesicles, 3
  48. Tian, 2021, Alleviates glioblastoma chemotoxicity without efficacy compromise, Nano Lett., 21, 5158, 10.1021/acs.nanolett.1c01201 · DOI

Cited by

Sorted by citations

Metadata

Authors
Wang, R., Liang, Q., Zhang, X., Di, Z., Wang, X., & Di, L.
Venue
Colloids and Surfaces B: Biointerfaces
Publisher
Elsevier BV
Published
2022-07
Volume
215
Pages
112505
ISSN
0927-7765
DOI
10.1016/j.colsurfb.2022.112505
Cited by
61
References
0
Language
en
Licence
Funders
  • Nanjing University of Chinese Medicine (NZY81903557)
  • Natural Science Foundation of Jiangsu Province (BK20190802)
  • National Natural Science Foundation of China (82074024, 81903557)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review